112 related articles for article (PubMed ID: 31178219)
1. Surrogates of immunologic cell death (ICD) and chemoradiotherapy outcomes in head and neck squamous cell carcinoma (HNSCC).
Economopoulou P; Koutsodontis G; Strati A; Kirodimos E; Giotakis E; Maragoudakis P; Prikas C; Papadimitriou N; Perisanidis C; Gagari E; Kotsantis I; Vagia E; Anastasiou M; Gkotzamanidou M; Kavourakis G; Lianidou E; Psyrri A
Oral Oncol; 2019 Jul; 94():93-100. PubMed ID: 31178219
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of indoleamine 2,3-dioxygenase 1
Economopoulou P; Kladi-Skandali A; Strati A; Koytsodontis G; Kirodimos E; Giotakis E; Maragoudakis P; Gagari E; Maratou E; Dimitriadis G; Kotsantis I; Vagia E; Anastasiou M; Gkotzamanidou M; Kavourakis G; Lianidou E; Psyrri A
ESMO Open; 2020 May; 5(3):e000646. PubMed ID: 32414944
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of circulating tumor cells with podoplanin expression in patients with locally advanced or metastatic head and neck squamous cell carcinoma.
Hsieh JC; Lin HC; Huang CY; Hsu HL; Wu TM; Lee CL; Chen MC; Wang HM; Tseng CP
Head Neck; 2015 Oct; 37(10):1448-55. PubMed ID: 24844673
[TBL] [Abstract][Full Text] [Related]
4. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
Seiwert TY; Melotek JM; Blair EA; Stenson KM; Salama JK; Witt ME; Brisson RJ; Chawla A; Dekker A; Lingen MW; Kocherginsky M; Villaflor VM; Cohen EE; Haraf DJ; Vokes EE
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):21-9. PubMed ID: 27511844
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of circulating tumor cells in patients with locally advanced head and neck squamous cell carcinoma.
Liu K; Chen N; Wei J; Ma L; Yang S; Zhang X
Oncol Rep; 2020 May; 43(5):1525-1535. PubMed ID: 32323844
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of the expression of epithelial cell adhesion molecules in head and neck squamous cell carcinoma treated by definitive radiotherapy.
Murakami N; Mori T; Nakamura S; Yoshimoto S; Honma Y; Ueno T; Kobayashi K; Kashihara T; Takahashi K; Inaba K; Okuma K; Igaki H; Nakayama Y; Itami J
J Radiat Res; 2019 Nov; 60(6):803-811. PubMed ID: 31361893
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of circulating tumor cells and their expression of EGFR/phospho-EGFR during combined radiotherapy regimens in locally advanced squamous cell carcinoma of the head and neck.
Tinhofer I; Hristozova T; Stromberger C; Keilhoiz U; Budach V
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e685-90. PubMed ID: 22583603
[TBL] [Abstract][Full Text] [Related]
8. Circulating free DNA as a marker of response to chemoradiation in locally advanced head and neck squamous cell carcinoma.
Verma T; Kumari S; Mishra S; Rastogi M; Tiwari V; Agarwal GR; Anand N; Husain N
Indian J Pathol Microbiol; 2020; 63(4):521-526. PubMed ID: 33154299
[TBL] [Abstract][Full Text] [Related]
9. MiR-200b and miR-155 as predictive biomarkers for the efficacy of chemoradiation in locally advanced head and neck squamous cell carcinoma.
Hess AK; Müer A; Mairinger FD; Weichert W; Stenzinger A; Hummel M; Budach V; Tinhofer I
Eur J Cancer; 2017 May; 77():3-12. PubMed ID: 28347920
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion.
Nyflot MJ; Kruser TJ; Traynor AM; Khuntia D; Yang DT; Hartig GK; McCulloch TM; Wiederholt PA; Gentry LR; Hoang T; Jeraj R; Harari PM
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):942-51. PubMed ID: 25659884
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of nutritional and hematologic markers in head and neck squamous cell carcinoma treated by chemoradiotherapy.
Moon H; Roh JL; Lee SW; Kim SB; Choi SH; Nam SY; Kim SY
Radiother Oncol; 2016 Feb; 118(2):330-4. PubMed ID: 26653356
[TBL] [Abstract][Full Text] [Related]
12. nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma.
Johnson KCC; Ley J; Oppelt P; Lu J; Gay HA; Daly M; Jackson R; Rich J; Pipkorn P; Paniello RC; Zevallos J; Thorstad W; Adkins DR
Med Oncol; 2019 Oct; 36(11):93. PubMed ID: 31595355
[TBL] [Abstract][Full Text] [Related]
13. Use of
Rudžianskas V; Korobeinikova E; Rudžianskienė M; Jaselskė E; Adlienė D; Šedienė S; Kulakienė I; Padervinskis E; Jurkienė N; Juozaitytė E
Medicina (Kaunas); 2018 Dec; 54(6):. PubMed ID: 30544718
[No Abstract] [Full Text] [Related]
14. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials.
Budach W; Bölke E; Kammers K; Gerber PA; Orth K; Gripp S; Matuschek C
Radiother Oncol; 2016 Feb; 118(2):238-43. PubMed ID: 26589131
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of pathological complete remission after preoperative irradiation in patients with locally advanced head and neck squamous cell carcinoma: re-analysis of a phase 3 clinical study.
Wang K; Yi J; Huang X; Qu Y; Luo J; Xiao J; Zhang S; Tang Y; Liu W; Xu G; Gao L; Xu Z; Liu S; Wang X
Radiat Oncol; 2019 Dec; 14(1):225. PubMed ID: 31831042
[TBL] [Abstract][Full Text] [Related]
16. Prognostic role of epiregulin/amphiregulin expression in recurrent/metastatic head and neck cancer treated with cetuximab.
Kogashiwa Y; Inoue H; Kuba K; Araki R; Yasuda M; Nakahira M; Sugasawa M
Head Neck; 2018 Nov; 40(11):2424-2431. PubMed ID: 30302873
[TBL] [Abstract][Full Text] [Related]
17. Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer.
Tang C; Chan C; Jiang W; Murphy JD; von Eyben R; Colevas AD; Pinto H; Lee-Enriquez N; Kong C; Le QT
Head Neck; 2015 Mar; 37(3):386-92. PubMed ID: 24431011
[TBL] [Abstract][Full Text] [Related]
18. Expression of immune-regulatory molecules in circulating tumor cells derived from patients with head and neck squamous cell carcinoma.
Chikamatsu K; Tada H; Takahashi H; Kuwabara-Yokobori Y; Ishii H; Ida S; Shino M
Oral Oncol; 2019 Feb; 89():34-39. PubMed ID: 30732956
[TBL] [Abstract][Full Text] [Related]
19. JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer.
Yu Y; Lee NY
Future Oncol; 2019 Mar; 15(7):687-694. PubMed ID: 30461306
[TBL] [Abstract][Full Text] [Related]
20. Toxicity profile and clinical outcomes in locally advanced head and neck cancer patients treated with induction chemotherapy prior to concurrent chemoradiation.
Ko EC; Genden EM; Misiukiewicz K; Som PM; Kostakoglu L; Chen CT; Packer S; Kao J
Oncol Rep; 2012 Feb; 27(2):467-74. PubMed ID: 22020564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
